The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s (GSK) challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
GSK, GlaxoSmithKline, Vectura, patent infringement, inhalers, Federal Circuit, Ellipta